🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› France
Clinical trial register · European Union · CTIS

Clinical Trials in France, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12479 total CTIS records — a stated recency window, not the full historical archive. Synced 24 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,479
Total on CTIS
full historical archive
743
Phase III
within the shown window
Top member states
Spain 1015 France 884 Germany 862 Italy 739 Poland 582 Netherlands 531
Narrow the registerReset
Phase
Phase I 555 Phase I/II 212 Phase II 730 Phase III 743 Phase IV 260
Lead sponsor
AstraZeneca AB 63 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1015 France 884 Germany 862 Italy 739 Poland 582 Netherlands 531 Belgium 431 Czechia 331
All 28 states

Trials with a site in France

884 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
BRECHE : Efficacy of sphenopalatine block compared to blood patch in the management of post-dural puncture syndrome.
2025-522168-34-00Post-dural puncture syndrome
University Hospital Of Clermont-Ferrand
Therapeutics
France
12/11/2025
Phase II
MATVAC-1 : EVALUATION OF UCPVAX VACCINE +/- PEMBROLIZUMAB COMBINED WITH STANDARD TREATMENT AS ADJUVANT THERAPY IN PATIENTS WITH UNMETHYLATED MGMT GLIOBLASTOMA
2024-514399-42-00Glioblastoma
Centre Hospitalier Regional Universitaire
Immune System Diseases
France
12/11/2025
Phase III
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02)
2024-513586-39-00Prostate Cancer
AstraZeneca AB
Male Urogenital Diseases
Austria, Sweden, Spain, France, Netherlands, Germany, Belgium, Finland, Hungary, Poland, Italy
12/11/2025
Phase I/II
A Phase I/II, Open-Label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors
2025-521441-24-00Advanced or Metastatic Solid Tumors
Alentis Therapeutics AG
Neoplasms
Spain, France, Netherlands, Italy
12/11/2025
Phase II
A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)
2025-521737-91-00Neoplasm malignant with KRAS G12C mutation
Merck Sharp & Dohme LLC
Neoplasms
Norway, Spain, Sweden, Italy, Denmark, France, Poland, Germany, Greece
12/11/2025
Phase I/II
A Phase I/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, and pharmacokinetics of BNT323 in combination with BNT327 in participants with advanced breast cancer
2024-517979-20-00Advanced Breast Cancer Metastatic Breast Cancer
BioNTech SE
Neoplasms
Italy, Spain, France
11/11/2025
Phase III
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor
2025-523083-21-00PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Gr…
Relay Therapeutics Inc.
Neoplasms
Hungary, Spain, Italy, Belgium, Netherlands, Austria, Germany, Greece, Czechia, Denmark, Poland, Bulgaria, Portugal, France, Ireland, Romania
11/11/2025
Phase III
ANTIBIOBONTA - Assessment of the interest of a peri-operative antibiotic strategy applied to patients with asymptomatic bacteriuria undergoing intra-vesical botulinum toxin A injections
2024-515107-19-00Patients (male or female) ≥18 years old with Detrusor overa…
Centre Hospitalier Universitaire De Lille
Nervous System Diseases
France
10/11/2025
Phase II
Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
2025-521242-26-00Moderately to Severely Active Ulcerative Colitis
Spyre Therapeutics Inc.
Digestive System Diseases
Belgium, Hungary, Lithuania, Netherlands, Croatia, Czechia, Bulgaria, Romania, Spain, France, Austria, Italy, Greece, Poland, Germany, Slovakia
10/11/2025
Phase III
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)
2024-517136-21-00Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Neoplasms
Greece, Germany, France, Italy, Croatia, Denmark, Czechia, Austria, Belgium, Ireland, Spain, Poland
10/11/2025
Phase II
A Phase 2 Randomized, Double-blind Placebo-Controlled Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety and Efficacy of WIN378 in Adult Participants with Moderate or Severe Asthma (the POLARIS trial)
2025-521391-58-00Asthma
Windward Bio AG
Respiratory Tract Diseases
Germany, France, Sweden, Bulgaria, Spain
10/11/2025
Phase III
A Phase 3, Multi-center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
2025-522862-58-00Locally advanced unresectable or metastatic gastric or gast…
BeOne Medicines AG
Neoplasms
Spain, France, Austria, Italy, Poland, Czechia
10/11/2025
Phase II
A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs. SCLEROCAR
2024-519511-33-00Patients will be included with a stable but active disease …
Centre Hospitalier Universitaire De Montpellier
Immune System Diseases
France
07/11/2025
Phase III
A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the pharmacokinetics, safety, and efficacy of empagliflozin tablets in paediatric patients with chronic kidney disease (EMPA-KIDNEY Kids)
2024-512577-27-00Chronic kidney disease in paediatric patients
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Nutritional and Metabolic Diseases
Spain, Germany, Portugal, Netherlands, Belgium, Poland, Italy, France, Sweden, Hungary
06/11/2025
Phase II
IFCT-2402 LAG-MAPS A non-comparative phase IIR trial assessing fianlimab plus cemiplimab plus pemetrexed-platinum chemotherapy or cemiplimab plus pemetrexed-platinum chemotherapy for treatment-naive Pleural Mesothelioma (PM) patients
2024-519208-29-00Pleural mesothelioma
Intergroupe Francophone De Cancerologie Thoracique
Neoplasms
France
06/11/2025
Phase II
Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously untreated symptomatic chronic lymphocytic leukemia (CLL). A phase II FILO trial
2025-521199-80-00Patients with previously untreated symptomatic chronic lymp…
French Innovative Leukemia Organization
Hemic and Lymphatic Diseases
France
05/11/2025
Phase II
An Open-label, Multinational Study Assessing the Efficacy and Safety of Dato-DXd Treatment in Patients With HR-positive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06)
2025-521904-23-00Locally Advanced Inoperable or Metastatic Breast Cancer Ref…
AstraZeneca AB
Neoplasms
Spain, France, Italy
05/11/2025
Phase III
Lidocaine for opioid sparing in vaso-occlusive crisis of Sickle Cell Disease
2024-518437-28-00Sickle cell disease
Centre Hospitalier Universitaire De Nantes
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France
05/11/2025
Phase III
A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults with Chronic Primary Immune Thrombocytopenia
2025-521692-31-00Chronic Primary Immune Thrombocytopenia
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
Bulgaria, Spain, Netherlands, Italy, Poland, Greece, Germany, France, Czechia, Croatia, Norway, Sweden
04/11/2025
Phase II
Efficacy and safety assessment of T1695 ophthalmic suspension, versus Ciclosporin ophthalmic emulsion, in participants with moderate to severe Vernal Keratoconjunctivitis (VKC)
2025-521567-12-00Vernal Keratoconjunctivitis (VKC)
Laboratoires Thea
Eye Diseases
Spain, Italy, Bulgaria, France, Greece
04/11/2025
Phase III
EORTC-2427-BTG: Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study (VIGOR)
2024-519404-27-00​​IDH-mutant grade 2 or 3 astrocytoma​
Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi
Neoplasms
Germany, France, Italy, Austria, Netherlands, Spain, Czechia, Belgium
04/11/2025
Phase III
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus trifluridine/tipiracil alone for metastatic oeso-gastric adenocarcinoma.
2025-522395-92-00metastatic oeso-gastric adenocarcinoma
Fondation Franc.Cancerologie Digestive
Neoplasms
France, Germany, Spain
04/11/2025
Phase III
A Phase III, Multicenter, Randomized, Double blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants with Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)
2024-518008-33-00Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia…
F. Hoffmann-La Roche AG
Nervous System Diseases
Poland, France, Germany, Netherlands, Spain, Italy, Denmark
04/11/2025
Phase III
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants with Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)
2024-518006-40-00Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia…
F. Hoffmann-La Roche AG
Nervous System Diseases
Spain, Poland, Italy, Denmark, France, Germany
04/11/2025
Phase III
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
2025-521012-18-00Facioscapulohumeral Muscular Dystrophy (FSHD)
Avidity Biosciences Inc.
Musculoskeletal Diseases
Italy, France, Germany, Spain, Denmark, Netherlands
04/11/2025
Phase II
A Seamless Phase 2a/2b, Randomized, Double-Blind, Placebo- and Active-Controlled, Multiple-Arm, Multiple-Stage, Adaptive Study Evaluating the Efficacy and Safety of LAD191 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
2025-521293-34-00Moderate-to-severe hidradenitis suppurativa
Almirall S.A.
Skin and Connective Tissue Diseases
Germany, Italy, Ireland, Poland, Spain, France
03/11/2025
Phase I/II
A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of GSK5458514 PSMA targeting T cell engager alone or in combination with other anti-cancer agents in adult participants with metastatic castration-resistant prostate cancer (mCRPC)
2025-521581-10-00Neoplasms, Prostate
Glaxosmithkline Research & Development Limited
Neoplasms
France, Spain
03/11/2025
Phase I/II
A Multicenter First-in-human Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of the 5T4 Antibody-Drug Conjugate TUB-030 in Patients with Advanced Solid Tumors (5-STAR 1-01)
2025-522517-35-00Patients with advanced/metastatic tumors with head and neck…
Tubulis GmbH
Neoplasms
France, Spain, Romania
03/11/2025
Phase III
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator’s Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
2024-519493-39-00High-risk Non-muscle-invasive Bladder Cancer with Susceptib…
Janssen Cilag International
Neoplasms
France, Germany, Spain, Netherlands, Italy, Belgium, Greece
03/11/2025
Phase III
A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children with Hypochondroplasia
2024-517238-16-00Hypochondroplasia
Biomarin Pharmaceutical Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France, Spain, Italy, Germany
03/11/2025
Phase III
A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants with Phenylketonuria
2024-519554-37-00Phenylketonuria
Otsuka Pharmaceutical Development & Commercialization Inc.
Nervous System Diseases
Czechia, Italy, Spain, Netherlands, Poland, France, Germany
03/11/2025
Phase III
A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
2025-521711-39-00Lewy body Dementia psychosis (LBDP)
Acadia Pharmaceuticals Inc.
Nervous System Diseases
Czechia, Italy, France, Bulgaria
03/11/2025
Phase III
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
2025-520555-89-00Metastatic castration-resistant prostate cancer (mCRPC)
Amgen Inc.
Neoplasms
Austria, Netherlands, Portugal, Spain, Belgium, Greece, France, Italy, Germany
03/11/2025
Phase II
A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 years of Age and Older With Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization
2025-523009-14-00Bronchiectasis with chronic pseudomonas aeruginosa coloniza…
AstraZeneca AB
Respiratory Tract Diseases
Netherlands, Italy, Greece, Denmark, Belgium, Spain, France, Germany
31/10/2025
Phase I
Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.
2024-516625-31-00Advanced Solid Tumor
Daiichi Sankyo Inc.
Neoplasms
Spain, France
30/10/2025
Phase III
Efficacy of Ursodeoxycholic Acid versus Corticosteroids for the Treatment of Cholestatic Hepatitis Secondary to Immunotherapy: A Multicenter, Controlled, Randomized, Open Trial
2025-521317-50-00Cholestatic hepatitis induced by immune checkpoint inhibito…
Centre Hospitalier Universitaire De Montpellier
Digestive System Diseases
France
30/10/2025
Phase III
Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care: the PEDIADEX randomized controlled trial
2025-521039-35-00Impact on delirium of the use of DEXmedetomidine as first-…
Centre Hospitalier Regional Universitaire De Tours
Anesthesia and Analgesia
France
29/10/2025
Phase II
A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults with Lewy Body Dementia Psychosis (LBDP)
2025-521710-25-00Lewy Body Dementia Psychosis (LBDP)
Acadia Pharmaceuticals Inc.
Nervous System Diseases
Bulgaria, Czechia, Italy, France
29/10/2025
Phase II
The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
2025-521144-38-00Primary Central Nervous System Lymphoma
Bristol-Myers Squibb Services Unlimited Company
Nervous System Diseases
France, Germany
29/10/2025
Phase II
NEOREM/NEO-1 - NEOREM : Neo-adjuvant Adaptive Master Trial for Localized Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / NEO-1 : Neo-adjuvant intratumoral Anti-CTLA4 + Anti-PD1 treatment in patients with localized melanoma
2025-522127-95-00NEOREM: Localized solid malignancies that are eligible to r…
Unicancer
Neoplasms
France
28/10/2025
Phase II
An open-label phase II trial to evaluate the clinical efficacy, safety and tolerability of MAS825 in pediatric and adult participants with Still’s disease
2024-520208-25-00Still’s disease
Novartis Pharma AG
Immune System Diseases
Italy, Netherlands, Spain, France, Germany
28/10/2025
Phase I
European, multicentre, single arm (phase I) trial of autologous skeletal muscle derived cell (ASMDC) microcarrier combination for the treatment of faecal incontinence (FI) in women with obstetric anal sphincter injury.
2023-504282-23-00Faecal incontinence
University College London
Female Urogenital Diseases and Pregnancy Complications
France, Spain, Austria, Denmark
28/10/2025
Phase I
AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors
2025-521707-48-00KRAS Altered Advanced or Metastatic Solid Tumors
Amgen Inc.
Neoplasms
France, Netherlands, Germany, Denmark, Spain, Italy, Belgium
28/10/2025
Phase II
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
2024-519820-26-00Hallucinations and Delusions Associated with Alzheimer’s Di…
Maplight Therapeutics Inc.
Nervous System Diseases
France, Czechia, Slovakia, Hungary, Portugal, Romania, Bulgaria, Italy, Poland
27/10/2025
Phase III
A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2- expressing recurrent endometrial cancer
2023-507525-42-00Endometrial cancer
BioNTech SE
Female Urogenital Diseases and Pregnancy Complications
Denmark, Poland, Italy, Finland, Czechia, Sweden, Greece, Belgium, Norway, Hungary, Germany, Austria, France, Spain, Netherlands
27/10/2025
Phase I
A Study Testing the Investigational Drug XmAb541 in people with Advanced Cancer
2025-521981-90-00Advanced Solid Tumors
Xencor Inc.
Neoplasms
Spain, France, Belgium, Denmark
27/10/2025
Phase III
68Ga-FAPI PET/CT imaging to assess pulmonary artery and right ventricle remodeling SoFAPI study
2025-520731-17-02Pulmonary arterial hypertension (PAH)
Centre Hospitalier Regional Et Universitaire De Brest
Diagnosis
France
24/10/2025
Phase II
BASECOVID - Bevacizumab in post-acute sequelae of COVID-19 : Efficacy and Safety (Pilot Study)
2024-520308-24-00Adult patients with persistent dyspnea more than 3 months a…
Assistance Publique Hopitaux De Paris
Virus Diseases
France
24/10/2025
Phase III
A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion.
2025-521511-40-00metastatic non-small cell lung cancer
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Greece, Czechia, France, Sweden, Romania, Belgium, Austria, Bulgaria, Italy, Netherlands, Denmark, Germany, Poland, Hungary, Spain
24/10/2025
Phase III
A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease
2025-521398-15-00Immune system diseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Netherlands, Spain, France, Belgium, Sweden, Germany, Poland, Italy
24/10/2025
Phase II
LUSPARA - A basket phase II clinical trial evaluating Luspatercept in patients affected with rare inherited anemias
2024-520200-26-00Inherited anemias
Eurobloodnet Association
Hemic and Lymphatic Diseases
Italy, France
24/10/2025
Phase II
ALTER : A Phase 2, Multicenter, Randomized, Open-label trial assessing sacituzumab-govitecan and trastuzumab-deruxtecan combinaison in an ALTERnating regimen for patients with metastatic or locally advanced Her2-low triple-negative breast Cancer
2025-521909-40-00Patients with metastatic or locally advanced HER2-low tripl…
Unicancer
Neoplasms
France
23/10/2025
Phase II
Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor
2025-520468-16-00Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced U…
Genmab A/S
Neoplasms
France, Spain, Netherlands, Germany
23/10/2025
Phase II
A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimer’s Disease.
2025-521107-42-00Alzheimer's Disease
Glaxosmithkline Research & Development Limited
Nervous System Diseases
Sweden, Norway, Italy, France, Spain, Finland, Netherlands, Germany
23/10/2025
Phase II
Preoperative use of Romiplostim in thrombocytopenic patients undergoing cardiac surgery. A Phase 3, multicenter randomized double-blinded controlled against placebo study
2024-517710-15-00thrombocytopenic patients undergoing cardiac surgery
Centre Hospitalier Universitaire De Nantes
Surgical Procedures, Operative
France
22/10/2025
Phase III
A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)
2024-513676-18-00Transthyretin Amyloidosis
Eidos Therapeutics Inc.
Cardiovascular Diseases
Germany, Portugal, Netherlands, France, Spain, Italy, Ireland, Belgium, Sweden, Denmark, Greece
22/10/2025
Phase II
A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants with Advanced Prostate Cancer
2024-517653-27-00Prostate Cancer
Astellas Pharma Global Development Inc.
Neoplasms
Italy, Poland, Spain, France, Germany
22/10/2025
Phase III
STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
2025-521352-38-00Hereditary Angioedema
Adarx Pharmaceuticals Inc.
Immune System Diseases
Belgium, Poland, Italy, Czechia, Hungary, Spain, Germany, Croatia, France, Bulgaria, Austria
22/10/2025
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-2)
2025-520612-34-00Agitation Associated with Alzheimer’s Disease
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Poland, Hungary, Italy, France, Czechia
22/10/2025
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia
2024-514401-54-00Chronic Primary Immune Thrombocytopenia
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
Poland, Spain, Bulgaria, Italy, Netherlands, Croatia, Germany, Sweden, Greece, Czechia, Norway, France
22/10/2025
Phase III
Prevention of RSV infection in infants by administering nirsevimab to infants, with or without maternal RSV vaccination: a randomised controlled trial in France as part of the Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)
2025-521755-23-00Respiratory syncytial virus infection, Bronchiolitis, Respi…
Centre Hospitalier Annecy Genevois
Health Care Economics and Organizations
France
21/10/2025
Phase III
CN012-0025: A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-3)
2024-519994-20-00Agitation Associated with Alzheimer’s Disease
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Croatia, Romania, France, Spain, Italy, Greece, Czechia, Bulgaria, Poland, Portugal, Hungary
21/10/2025
Phase II
A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects <2 Years Old With Spinal Muscular Atrophy (SMA) (OPAL)
2024-520130-29-00Spinal Muscular Atrophy
Scholar Rock Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Belgium, France, Italy, Spain, Netherlands
21/10/2025
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 2)
2025-520747-32-00Mild to moderate Alzheimer’s Disease
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Germany, Netherlands, Portugal, France, Spain, Poland, Greece, Romania, Italy, Finland
21/10/2025
Phase III
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
2024-518365-10-00Previously Untreated Advanced or Metastatic Non-Squamous No…
F. Hoffmann-La Roche AG
Neoplasms
Ireland, Greece, Hungary, Netherlands, France, Denmark, Germany, Poland, Italy, Portugal, Spain, Belgium
21/10/2025
Phase II
BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, multicenter, comparative, randomized GERCOR G-124 BETWEEN phase II study
2024-520128-27-00colorectal adenocarcinoma
Association Gercor
Digestive System Diseases
France
20/10/2025
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children with Hypochondroplasia, Aged 0 to < 36 Months
2024-512261-14-00Hypochondroplasia
Biomarin Pharmaceutical Inc.
Genetic Phenomena
Germany, Italy, France
20/10/2025
Phase III
A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-through 3-year-old Children with Peanut Allergy
2025-521697-34-00Peanut allergy
Dbv Technologies
Immune System Diseases
Spain, France, Netherlands, Ireland
20/10/2025
Phase III
C4551002 - An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Adult Participants with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy
2025-520566-22-00Hormone Receptor-Positive, HER2-Negative Advanced/Metastati…
Pfizer Inc.
Neoplasms
Hungary, Bulgaria, Czechia, Slovakia, Netherlands, Spain, Greece, Finland, Belgium, Sweden, Poland, Germany, France, Italy
20/10/2025
Phase III
The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study
2024-519976-19-00Asthma with type 2 inflammation characterized by an eosinop…
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Belgium, Spain, Italy, Greece, France, Germany
20/10/2025
Phase II
EPIK-P4: A Phase II single arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)
2024-519960-42-00PIK3CA-Related Overgrowth Spectrum (PROS)
Novartis Pharma AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Italy, Netherlands, Belgium, Spain, Austria, Germany, France
20/10/2025
Phase II
PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.
2024-519753-11-00Resectable borderline pancreatic adenocarcinoma
Fondation Franc.Cancerologie Digestive
Digestive System Diseases
France
17/10/2025
Phase III
IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment
2024-519871-24-00Breast cancer, Triple-negative breast cancer
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
France, Portugal, Romania, Greece, Italy, Spain, Sweden, Austria, Poland, Germany
17/10/2025
Phase II
Efficacy of probenecid on cluster seizures during dosage reduction of Anti Seizure Medication (ASM) in presurgical focal epilepsy video-EEG monitoring
2024-519133-29-00Focal epilepsy
Fondation A De Rothschild
Nervous System Diseases
France
17/10/2025
Phase IV
Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.
2024-516232-10-00Serious infections in critically ill patients treated with …
Centre Hospitalier Universitaire De Nimes
Bacterial Infections and Mycoses
France
17/10/2025
Phase III
Efficacy of non operative treatment with amoxicillin/clavulanic acid versus surgical treatment in acute uncomplicated appendicitis in children: a prospective multicenter randomized controlled non-inferiority trial with cost utility analysis
2024-519402-12-00uncomplicated appendicitis
Centre Hospitalier Universitaire De Toulouse
Digestive System Diseases
France
17/10/2025
Phase III
SERORL Effect of aspirin and folic acid for sudden sensorineural hearing loss
2024-513710-35-00Patients presenting to ENT emergencies with a unilateral su…
Assistance Publique Hopitaux De Paris
Otorhinolaryngologic Diseases
France
17/10/2025
Phase II
Methotrexate treatment in hand osteoarthritis refractory to usual treatments: A randomised, double-blind, placebo-controlled trial, ADEM2 study
2022-502362-24-00Erosive osteoarthritis
Centre Hospitalier Universitaire De Nice
Musculoskeletal Diseases
France
17/10/2025
Phase III
PROlonged Corticosteroid treatment or N-ACetylcysteine for severe alcoholic hepatitis (PROCORNAC)
2025-522109-39-00Alcoholic hepatitis
Centre Hospitalier Universitaire De Lille
Digestive System Diseases
France
17/10/2025
Phase III
PRODIGE 118 - PEHRICCA : PErioperative CISGEM plus RILVEGOSTOMIG in High-Risk resectable Intrahepatic CholangioCarcinoma Phase II single arm study -mutlicenter
2025-521302-17-00Hihg risk of cholangiocarcinoma intra hépatic resectable
Fondation Franc.Cancerologie Digestive
Neoplasms
France
15/10/2025
Phase II
A phase 2, two-part study to assess the safety, antiviral biomarker responses, and efficacy of inhaled SNG001 for the treatment of patients with a confirmed respiratory virus infection undergoing invasive mechanical ventilation
2024-520375-27-00Lower respiratory tract viral infections
Synairgen Research Limited
Virus Diseases
Netherlands, France, Spain, Belgium
15/10/2025
Phase III
A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed During or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment. TROPION-Urothelial03 (TU03).
2024-516906-47-00Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo Inc.
Neoplasms
Netherlands, Germany, Norway, Denmark, France, Austria, Italy, Spain, Belgium, Czechia, Greece
15/10/2025
Phase III
B7981027 - A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA
2024-515438-33-00Alopecia areata
Pfizer Inc.
Immune System Diseases
Spain, France, Czechia, Italy, Poland
14/10/2025
Phase III
TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy)
2024-519917-72-00Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloid…
Alnylam Pharmaceuticals Inc.
Cardiovascular Diseases
France, Germany, Italy, Greece, Belgium, Portugal, Netherlands, Austria, Sweden, Denmark, Spain, Czechia, Hungary, Ireland, Romania, Norway, Poland, Slovakia
14/10/2025
Phase III
B7981028 - A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031
2024-515439-31-00Alopecia areata
Pfizer Inc.
Immune System Diseases
Italy, France, Czechia, Poland, Spain
14/10/2025
Phase III
J2O-MC-EKBG: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event - MOVE-Lp(a)
2025-521067-13-00Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASC…
Eli Lilly & Co.
Cardiovascular Diseases
Italy, Poland, Germany, Austria, Romania, Spain, Czechia, France, Denmark, Greece, Hungary, Slovakia, Belgium, Netherlands
13/10/2025
Phase III
A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients with Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX-3)
2025-521785-10-00Glioblastoma
Telix Pharmaceuticals (Innovations) Pty Limited
Neoplasms
Austria, Netherlands, Belgium, Denmark, France, Germany, Spain
13/10/2025
Phase II
Role of Neuroinflammation and Blood-Brain Barrier Breakdown in Intracerebral Hemorrhage. The INFINITE Study
2025-521923-58-00Intracerebral hemorrhage.
Centre Hospitalier Universitaire De Toulouse
Nervous System Diseases
France
10/10/2025
Phase I
A phase 1, Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt (EYP651) and Evaluation of Potential Drug-Drug Interactions.
2025-522915-40-00Healthy volunteers, Impaired renal function and suspected M…
ENYO Pharma
Digestive System Diseases
France
09/10/2025
Phase III
Impact of low dose epinephrine in the management of out-of-hospital cardiac arrest on neurological outcome: A multicenter randomized and double-blind trial (Low-EPI Study)
2023-505349-26-00Out-of-hospital cardiac arrest.
CHRU De Nancy
Cardiovascular Diseases
France
08/10/2025
Phase IV
Influence of patient’s morphological characteristics on pharmacokinetic and toxicity of trastuzumab-deruxtecan administered for metastatic breast cancers (TDXdose)
2025-522656-68-00Metastatic breast cancers
Oncopole Claudius Regaud
Neoplasms
France
08/10/2025
Phase II
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.
2024-519258-35-00stomach cancer, Esophage, gastro-oesophageal junction adeno…
Fondation Franc.Cancerologie Digestive
Digestive System Diseases
France
08/10/2025
Phase II
PRODIGE 115 (FFCD 2406) ULYSSE : A phase II, open-label, non-comparative, randomized study of second-line doublet chemotherapy (FOLFOX or FOLFIRI) plus Fruquintinib versus doublet chemotherapy (FOLFOX or FOLFIRI) plus Bevacizumab in metastatic colorectal cancer
2025-522108-26-00métastatique colorectal cancer
Fondation Franc.Cancerologie Digestive
Digestive System Diseases
France
08/10/2025
Phase II
GFM-VEXAS-MMB: A single-arm phase II with safety run-in multicenter study of momelotinib in patients with VEXAS syndrome with or without associated myelodysplastic syndrome
2024-519779-24-00VEXAS (VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, SOM…
Groupe Francophone Des Myelodysplasies
Immune System Diseases
France
08/10/2025
Phase II
C4921003 - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Oral Branched-Chain Ketoacid Dehydrogenase Kinase Inhibitor, PF-07328948 in Adults with Heart Failure (BRANCH-HF)
2024-518438-94-00Heart failure
Pfizer Inc.
Cardiovascular Diseases
France, Spain, Bulgaria, Poland, Hungary, Czechia
08/10/2025
Phase II
A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
2025-521277-14-00Non-muscle invasive bladder cancer (NMIBC)
Tyra Biosciences Inc.
Neoplasms
Italy, Spain, France
08/10/2025
Phase III
ETOP 27-23 ARCH – A randomised phase III trial of adjuvant cemiplimab in patients with resected stage IIA-IIIB NSCLC who have not received prior adjuvant chemotherapy.
2024-519901-36-00Patients with resected stage IIA-IIIB non-small cell lung c…
ETOP IBCSG Partners Foundation
Neoplasms
France, Estonia, Spain, Austria, Italy, Germany, Ireland
08/10/2025
Phase III
Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity
2024-519530-24-00Overweight and obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Norway, France, Italy, Germany, Poland
07/10/2025
Phase II
CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental disorders
2025-521161-27-00Children and adolescents with severe neurodevelopmental dis…
Assistance Publique Hopitaux De Paris
Behavior and Behavior Mechanisms
France
07/10/2025
Phase III
Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study)
2024-518385-26-01Polymyalgia Rheumatica (PMR)
Centre Hospitalier Regional Et Universitaire De Brest
Immune System Diseases
France
07/10/2025
Rows per page Showing 701–800 of 884
Previous 6 7 8 9 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-europe/country/france?page=8

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,479 trial records at the last sync on 24 Sep 2026, 03:17 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 884 of those trials with a site in France.

How many recently authorised EU trials have a site in France?

884 of the 2,500 most recently authorised trials in this register list a site in France; 408 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.